Toxic Effects Associated With the Administration of Deferoxamine in the Premature Baboon With Hyaline Membrane Disease

Robert A. deLemos, James A. deLemos, Dale R. Gerstmann, Donald Null

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

• We hypothesized that administration of the iron chelator deferoxamine would inhibit iron-catalyzed free radical generation and lessen the severity of oxygeninduced pulmonary injury. To evaluate its efficacy and safety in premature infants, we administered deferoxamine by intravenous infusion to five premature baboons with hyaline membrane disease supported with conventional ventilation and 100% oxygen for 6 days. Seven animals served as controls. Deferoxamine treatment was initiated at 10 mg/kg per hour but, after the precipitous death of the first animal, was progressively reduced to 1.25 mg/kg per hour in the other animals. Four of five deferoxamine-treated baboons developed cardiovascular collapse and all five died by 42 hours. Five of the seven control animals survived the 6-day expermental period. Since cardiovascular toxic effects have not previously been reported, these findings suggest unique vulnerability of the immature cardiovascular system to iron chelation.

Original languageEnglish (US)
Pages (from-to)915-919
Number of pages5
JournalAmerican Journal of Diseases of Children
Volume144
Issue number8
DOIs
StatePublished - Jan 1 1990
Externally publishedYes

Fingerprint

Hyaline Membrane Disease
Deferoxamine
Papio
Poisons
Iron
Lung Injury
Chelating Agents
Cardiovascular System
Intravenous Infusions
Premature Infants
Free Radicals
Ventilation
Oxygen
Safety

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Toxic Effects Associated With the Administration of Deferoxamine in the Premature Baboon With Hyaline Membrane Disease. / deLemos, Robert A.; deLemos, James A.; Gerstmann, Dale R.; Null, Donald.

In: American Journal of Diseases of Children, Vol. 144, No. 8, 01.01.1990, p. 915-919.

Research output: Contribution to journalArticle

@article{108bf87766224da9b6761ef11c5fd43a,
title = "Toxic Effects Associated With the Administration of Deferoxamine in the Premature Baboon With Hyaline Membrane Disease",
abstract = "• We hypothesized that administration of the iron chelator deferoxamine would inhibit iron-catalyzed free radical generation and lessen the severity of oxygeninduced pulmonary injury. To evaluate its efficacy and safety in premature infants, we administered deferoxamine by intravenous infusion to five premature baboons with hyaline membrane disease supported with conventional ventilation and 100{\%} oxygen for 6 days. Seven animals served as controls. Deferoxamine treatment was initiated at 10 mg/kg per hour but, after the precipitous death of the first animal, was progressively reduced to 1.25 mg/kg per hour in the other animals. Four of five deferoxamine-treated baboons developed cardiovascular collapse and all five died by 42 hours. Five of the seven control animals survived the 6-day expermental period. Since cardiovascular toxic effects have not previously been reported, these findings suggest unique vulnerability of the immature cardiovascular system to iron chelation.",
author = "deLemos, {Robert A.} and deLemos, {James A.} and Gerstmann, {Dale R.} and Donald Null",
year = "1990",
month = "1",
day = "1",
doi = "10.1001/archpedi.1990.02150320079032",
language = "English (US)",
volume = "144",
pages = "915--919",
journal = "JAMA Pediatrics",
issn = "2168-6203",
publisher = "American Medical Association",
number = "8",

}

TY - JOUR

T1 - Toxic Effects Associated With the Administration of Deferoxamine in the Premature Baboon With Hyaline Membrane Disease

AU - deLemos, Robert A.

AU - deLemos, James A.

AU - Gerstmann, Dale R.

AU - Null, Donald

PY - 1990/1/1

Y1 - 1990/1/1

N2 - • We hypothesized that administration of the iron chelator deferoxamine would inhibit iron-catalyzed free radical generation and lessen the severity of oxygeninduced pulmonary injury. To evaluate its efficacy and safety in premature infants, we administered deferoxamine by intravenous infusion to five premature baboons with hyaline membrane disease supported with conventional ventilation and 100% oxygen for 6 days. Seven animals served as controls. Deferoxamine treatment was initiated at 10 mg/kg per hour but, after the precipitous death of the first animal, was progressively reduced to 1.25 mg/kg per hour in the other animals. Four of five deferoxamine-treated baboons developed cardiovascular collapse and all five died by 42 hours. Five of the seven control animals survived the 6-day expermental period. Since cardiovascular toxic effects have not previously been reported, these findings suggest unique vulnerability of the immature cardiovascular system to iron chelation.

AB - • We hypothesized that administration of the iron chelator deferoxamine would inhibit iron-catalyzed free radical generation and lessen the severity of oxygeninduced pulmonary injury. To evaluate its efficacy and safety in premature infants, we administered deferoxamine by intravenous infusion to five premature baboons with hyaline membrane disease supported with conventional ventilation and 100% oxygen for 6 days. Seven animals served as controls. Deferoxamine treatment was initiated at 10 mg/kg per hour but, after the precipitous death of the first animal, was progressively reduced to 1.25 mg/kg per hour in the other animals. Four of five deferoxamine-treated baboons developed cardiovascular collapse and all five died by 42 hours. Five of the seven control animals survived the 6-day expermental period. Since cardiovascular toxic effects have not previously been reported, these findings suggest unique vulnerability of the immature cardiovascular system to iron chelation.

UR - http://www.scopus.com/inward/record.url?scp=0025364729&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025364729&partnerID=8YFLogxK

U2 - 10.1001/archpedi.1990.02150320079032

DO - 10.1001/archpedi.1990.02150320079032

M3 - Article

VL - 144

SP - 915

EP - 919

JO - JAMA Pediatrics

JF - JAMA Pediatrics

SN - 2168-6203

IS - 8

ER -